Search Results 1-10 of 16612 for Certolizumab

  1. Certolizumab (subcutaneous route) - Side effects & dosage - Mayo Clinic

    Certolizumab can temporarily lower the number of white blood cells in your blood, increasing the chance of getting an infection. It can also lower the number of ...

  2. Multicenter Study Evaluating Certolizumab Pegol Compared to Placebo in Subjects With axSpA Without X-ray Evidence of AS - Mayo Clinic

    ... certolizumab pegol (CZP) 200 mg every two weeks or placebo. The primary objective is to demonstrate the efficacy of CZP in these patients. Participation ...

  3. Spondyloarthritis Clinical Trials - Mayo Clinic Research

    ... certolizumab pegol (CZP) 200 mg every two weeks or placebo. The primary objective is to demonstrate the efficacy of CZP in these patients. GI and ...

  4. Inflammatory Arthritis Clinical Trials - Mayo Clinic Research

    ... certolizumab pegol (CZP) 200 mg every two weeks or placebo. The primary objective is to demonstrate the efficacy of CZP in these patients. Shared ...

  5. Study to Determine Risk Factors for Post-operative Infection in Inflammatory Bowel Disease - Mayo Clinic

    ... certolizumab. However, many CD and UC patients still ultimately require surgery despite the use of these medications. Side effects of the anti-TNF agents ...

  6. Study to Determine Risk Factors for Post-operative Infection in Inflammatory Bowel Disease - Mayo Clinic

    ... certolizumab. However, many CD and UC patients still ultimately require surgery despite the use of these medications. Side effects of the anti-TNF agents ...

  7. Treatment response and management of biologics in patients with ECD - Mayo Clinic

    These include tumor necrosis factor-alpha (TNFα) inhibitors (certolizumab, infliximab, adalimumab), anti-integrin agents (vedolizumab, natalizumab), and ...

  8. A Study to Assess Whether Etrolizumab is a Safe and Effective Treatment for Participants with Moderately to Severely Active Crohn's Disease (CD) - Mayo Clinic

    ... certolizumab pegol [≥ 400 mg]). Inadequate secondary non-response: Initially responded to induction therapy with infliximab (≥ 5 mg/kg) or adalimumab ...

  9. A Study of CNTO 136 (Sirukumab), a Human Anti-IL-6 Monoclonal Antibody, Administered Subcutaneously, in Patients With Active Rheumatoid Arthritis Despite Anti-TNF-Alpha Therapy (SIRROUND-T) - Mayo Clinic

    ... certolizumab pegol therapy and/or at least a 14-week dosage regimen (ie, at least 4 doses) of infliximab; Intolerance to at least 2 anti-TNF-alpha biologic ...

  10. Inflammatory Bowel Disease Treatment And Response To Therapy - Mayo Clinic

    ... certolizumab) due to loss of response, or incomplete response of current medication. Loss of response – objective flare after initial response. Incomplete ...